- Home
- KRNY vs XERS Comparison
KRNY vs XERS Comparison
Compare KRNY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNY
- XERS
- Stock Information
- Founded
- KRNY 1884
- XERS 2005
- Country
- KRNY United States
- XERS United States
- Employees
- KRNY N/A
- XERS N/A
- Industry
- KRNY Savings Institutions
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- KRNY Finance
- XERS Health Care
- Exchange
- KRNY Nasdaq
- XERS Nasdaq
- Market Cap
- KRNY 444.6M
- XERS 526.3M
- IPO Year
- KRNY 2005
- XERS 2018
- Fundamental
- Price
- KRNY $6.82
- XERS $3.75
- Analyst Decision
- KRNY Buy
- XERS Strong Buy
- Analyst Count
- KRNY 2
- XERS 4
- Target Price
- KRNY $7.75
- XERS $5.15
- AVG Volume (30 Days)
- KRNY 335.0K
- XERS 1.8M
- Earning Date
- KRNY 01-30-2025
- XERS 03-05-2025
- Dividend Yield
- KRNY 6.45%
- XERS N/A
- EPS Growth
- KRNY N/A
- XERS N/A
- EPS
- KRNY N/A
- XERS N/A
- Revenue
- KRNY $148,070,000.00
- XERS $187,361,000.00
- Revenue This Year
- KRNY N/A
- XERS $25.11
- Revenue Next Year
- KRNY $24.88
- XERS $19.29
- P/E Ratio
- KRNY N/A
- XERS N/A
- Revenue Growth
- KRNY N/A
- XERS 22.72
- 52 Week Low
- KRNY $5.28
- XERS $1.69
- 52 Week High
- KRNY $8.59
- XERS $4.10
- Technical
- Relative Strength Index (RSI)
- KRNY 39.62
- XERS 57.32
- Support Level
- KRNY $7.11
- XERS $3.51
- Resistance Level
- KRNY $7.36
- XERS $4.10
- Average True Range (ATR)
- KRNY 0.22
- XERS 0.17
- MACD
- KRNY -0.02
- XERS 0.03
- Stochastic Oscillator
- KRNY 19.23
- XERS 46.15
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. It is also heavily into secured and unsecured business and consumer loans. The bank's primary source of income is net interest income.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.